OGSG2101:Efficacy and Safety of BEACON triplet regimen for early relapse BRAF-mutated colorectal cancer

ABSTRACT: Interventions: Encorafenib,binimetinib,cetuximab Primary outcome(s): Objective response rate Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Braf V600e-mutated Colorectal Cancer

PROVIDER: 2615453 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR